CytomX Therapeutics (CTMX) Operating Margin (2016 - 2025)
Historic Operating Margin for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to 264.43%.
- CytomX Therapeutics' Operating Margin fell 2767300.0% to 264.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.46%, marking a year-over-year increase of 151600.0%. This contributed to the annual value of 18.1% for FY2024, which is 245100.0% up from last year.
- According to the latest figures from Q3 2025, CytomX Therapeutics' Operating Margin is 264.43%, which was down 2767300.0% from 6.89% recorded in Q2 2025.
- In the past 5 years, CytomX Therapeutics' Operating Margin registered a high of 46.41% during Q4 2024, and its lowest value of 354.67% during Q1 2022.
- In the last 5 years, CytomX Therapeutics' Operating Margin had a median value of 33.65% in 2024 and averaged 123.39%.
- In the last 5 years, CytomX Therapeutics' Operating Margin skyrocketed by 3306100bps in 2023 and then plummeted by -2767300bps in 2025.
- Quarter analysis of 5 years shows CytomX Therapeutics' Operating Margin stood at 313.54% in 2021, then soared by 85bps to 47.25% in 2022, then surged by 95bps to 2.28% in 2023, then soared by 2138bps to 46.41% in 2024, then tumbled by -670bps to 264.43% in 2025.
- Its Operating Margin stands at 264.43% for Q3 2025, versus 6.89% for Q2 2025 and 44.43% for Q1 2025.